SG11201408750VA - NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS - Google Patents
NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORSInfo
- Publication number
- SG11201408750VA SG11201408750VA SG11201408750VA SG11201408750VA SG11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bld29
- disheng
- daxing
- bpu
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 2
- 238000011161 development Methods 0.000 abstract 2
- 230000018109 developmental process Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012077924 | 2012-06-29 | ||
| PCT/CN2013/078592 WO2014000713A1 (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408750VA true SG11201408750VA (en) | 2015-01-29 |
Family
ID=49782283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408750VA SG11201408750VA (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Country Status (14)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| CA2990752C (en) | 2015-07-20 | 2020-03-10 | Betta Pharmaceuticals Co., Ltd | Crystalline form of fused pyridine derivative's maleate and uses thereof |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| CA3012832A1 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1 |
| WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3064975A1 (en) * | 2017-05-26 | 2018-11-29 | Glenmark Pharmaceuticals S.A. | Novel inhibitors of map4k1 |
| CN110461841B (zh) * | 2017-06-19 | 2020-09-15 | 上海和誉生物医药科技有限公司 | 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 |
| CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
| KR20210111779A (ko) * | 2018-12-14 | 2021-09-13 | 베타 파마, 인크. | C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TWI812302B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Ｌｇ化學股份有限公司 | 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物 |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
| EP4289427A1 (en) * | 2022-06-10 | 2023-12-13 | Anagenesis Biotechnologies | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4750701B2 (ja) * | 2003-07-07 | 2011-08-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | マロンアミド誘導体 |
| DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AU2005270068B2 (en) * | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| KR101257343B1 (ko) * | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| EP1827434B1 (en) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ES2473341T3 (es) | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
| EP2079738A2 (en) * | 2006-10-27 | 2009-07-22 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| KR20110075016A (ko) * | 2008-10-14 | 2011-07-05 | 닝 시 | 화합물 및 사용 방법 |
| KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
| CN102086211B (zh) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
| EP2593462B1 (en) * | 2010-07-14 | 2016-09-07 | Betta Pharmaceuticals Co., Ltd. | Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors |
-
2013
- 2013-06-29 TW TW102123415A patent/TWI520962B/zh not_active IP Right Cessation
- 2013-07-01 JP JP2015518816A patent/JP6059342B2/ja not_active Expired - Fee Related
- 2013-07-01 WO PCT/CN2013/078592 patent/WO2014000713A1/en active Application Filing
- 2013-07-01 AU AU2013283993A patent/AU2013283993B2/en not_active Ceased
- 2013-07-01 BR BR112014032745-9A patent/BR112014032745B1/pt not_active IP Right Cessation
- 2013-07-01 CA CA2878049A patent/CA2878049C/en not_active Expired - Fee Related
- 2013-07-01 IN IN372DEN2015 patent/IN2015DN00372A/en unknown
- 2013-07-01 EP EP13809182.2A patent/EP2867223B1/en not_active Not-in-force
- 2013-07-01 RU RU2015102057A patent/RU2619130C2/ru active
- 2013-07-01 SG SG11201408750VA patent/SG11201408750VA/en unknown
- 2013-07-01 KR KR1020177003331A patent/KR101770545B1/ko not_active Expired - Fee Related
- 2013-07-01 ES ES13809182T patent/ES2698511T3/es active Active
- 2013-07-01 US US14/411,515 patent/US9617257B2/en not_active Expired - Fee Related
- 2013-07-01 KR KR1020157002238A patent/KR101726522B1/ko not_active Expired - Fee Related
- 2013-07-01 KR KR1020177003335A patent/KR101726555B1/ko not_active Expired - Fee Related
-
2015
- 2015-01-16 ZA ZA2015/00344A patent/ZA201500344B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2878049C (en) | 2016-12-13 |
| US9617257B2 (en) | 2017-04-11 |
| RU2015102057A (ru) | 2016-08-20 |
| EP2867223A1 (en) | 2015-05-06 |
| KR20150031320A (ko) | 2015-03-23 |
| KR101726555B1 (ko) | 2017-04-12 |
| BR112014032745B1 (pt) | 2022-01-04 |
| IN2015DN00372A (enrdf_load_stackoverflow) | 2015-06-12 |
| JP6059342B2 (ja) | 2017-01-11 |
| TW201418254A (zh) | 2014-05-16 |
| KR20170017014A (ko) | 2017-02-14 |
| KR20170017015A (ko) | 2017-02-14 |
| KR101726522B1 (ko) | 2017-04-12 |
| AU2013283993A1 (en) | 2015-02-05 |
| CA2878049A1 (en) | 2014-01-03 |
| TWI520962B (zh) | 2016-02-11 |
| EP2867223B1 (en) | 2018-09-05 |
| ZA201500344B (en) | 2016-08-31 |
| RU2619130C2 (ru) | 2017-05-12 |
| ES2698511T3 (es) | 2019-02-05 |
| WO2014000713A1 (en) | 2014-01-03 |
| HK1207642A1 (en) | 2016-02-05 |
| EP2867223A4 (en) | 2016-01-06 |
| JP2015521634A (ja) | 2015-07-30 |
| KR101770545B1 (ko) | 2017-08-22 |
| BR112014032745A2 (pt) | 2017-06-27 |
| AU2013283993B2 (en) | 2016-07-07 |
| US20150315210A1 (en) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |